http://www.fpnotebook.com/
AlprazolamAka: Xanax
- See Also
- Pharmacokinetics
- Half Life: 12-15 hours
- Dosing
- Dose: 0.25 to 0.5 mg PO bid to tid
- Maximum Daily Dose: 4 mg
- Risks
- Very difficult to wean due to addictive potential
- Avoid if Chemical Dependency history
- Equivalent Dosing (for Benzodiazepine Withdrawal)
- Valium = Dose x10
- Phenobarbital = Dose x30
Alprazolam (C0002333) | |
|---|---|
| Definition (MSH) | A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238) |
| Definition (CSP) | 8-chloro-1-methyl-6-phenyl-s-triazolo benzodiazepine, has both antidepressant and anxiolytic properties; possible efficacy in alcohol withdrawal therapy; abuse can lead to habituation or addiction. |
| Definition (PDQ) | A triazolobenzodiazepine agent with anxiolytic, sedative-hypnotic and anticonvulsant activities. Alprazolam binds to a specific site distinct from the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) binding site on the benzodiazepine-GABA-A-chloride ionophore receptor complex located in the limbic, thalamic and hypothalamic regions of the central nervous system (CNS). This binding causes an allosteric modification of the receptor and enhances the affinity of GABA to the receptor leading to an increase in the frequency of chloride-channel opening events. This leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential and leads to a decrease in neuronal excitability. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39659&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39659&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C227" NCI Thesaurus) |
| Definition (NCI) | A triazolobenzodiazepine agent with anxiolytic, sedative-hypnotic and anticonvulsant activities. Alprazolam binds to a specific site distinct from the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) binding site on the benzodiazepine-GABA-A-chloride ionophore receptor complex located in the limbic, thalamic and hypothalamic regions of the central nervous system (CNS). This binding causes an allosteric modification of the receptor and enhances the affinity of GABA to the receptor leading to an increase in the frequency of chloride-channel opening events. This leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential and leads to a decrease in neuronal excitability. |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D000525 |
| English | Alprazolam, Alprazolam - chemical, ALPRAZOLAM PREPARATION, Alprazolan |
| Spanish | alprazolam |
| Parent Concepts | Benzodiazepines (C0005064), Hypnotics and Sedatives (C0020592), [CN302] BENZODIAZEPINE DERIVATIVE, SEDATIVES/HYPNOTICS (C0973503), Benzodiazepine sedative (C0360114), Anti-Anxiety Agents (C0040616), Duplicate concept (C1274013) |
| Sources | AOD, CSP, LCH, LNC, MSH, MTHSPL, NCI, NDFRT, PDQ, RXNORM, SCTSPA, SNOMEDCT, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Xanax (C0699034) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D000525 |
| English | Alprazolam Pharmacia Brand, Alprazolam Upjohn Brand, Pharmacia Brand of Alprazolam, Tafil, Trankimazin, Upjohn Brand of Alprazolam, Xanax |
| Sources | CSP, MSH, MTH, NCI, PDQ, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
